
StudyFinder
Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Status: Recruiting
This study looks at how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments
Sex: Male or Female
Age Group: 18 years and over
Inclusion Criteria:
• planning to receive Immune Checkpoint Therapy (ICI) for a solid tumor cancer
• if received prior ICI-based therapy must have completed it at least 180 days before starting the study
• must be able to complete Patient-Reported Outcome (PRO) forms in English, Spanish, or French
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Conditions:
Cancer
Keywords:
cancer, ICI, Immune Checkpoint Therapy, solid tumor
Study Contact: Kristen Nelson - knelso65@fairview.org
Principal Investigator: Puneet Cheema
IRB Number: MMCORC082
See this study on ClinicalTrials.gov